Ciwon daji
Ciwon daji na hanta wani nau'in ciwon daji ne na al'ada, kuma tasoshin jini suna taka muhimmiyar rawa wajen bunkasa ciwon hanta. Sabili da haka, maganin ciwon hanta da aka yi niyya na yanzu ana gudanar da shi a kusa da anti-angiogenesis. Maganin anti-angiogenesis hanya ce mai mahimmanci a cikin aikin asibiti na ciwon hanta.
KAI 2 GWAJI
The REACH-2 trial is carried out on the basis of the REACH trial. The Chinese American scholar Professor Andrew X. Zhu of the Massachusetts Hospital affiliated to Harvard University in the United States serves as the global PI. For the ciwon daji patients who failed to treat Sorafenib, the comparison Ramucirumab differed from placebo in the efficacy of second-line treatment, but the trial did not achieve the expected results. But its subgroup analysis shows that patients with AFP (alpha-fetoprotein) over 400 ng / ml can benefit from Ramucirumab treatment. Therefore, Professor Zhu led the REACH-2 trial and found that Ramucirumab benefits patients both in overall survival and progression-free survival time compared with placebo. This test has epoch-making significance, and it further proves that in the second-line treatment of liver cancer, anti-angiogenesis treatment with macromolecular monoclonal antibodies can achieve clinically meaningful survival benefits.
A halin yanzu, an amince da oxaliplatin a matsayin daidaitaccen tsarin kulawa a cikin gida da ƙasashen Turai. Don ƙananan kwayoyin da aka yi niyya, ana iya amfani da sorafenib da lenvatinib don maganin farko, kuma ana amfani da regorafenib da carbotinib don maganin layi na biyu. Don manyan ƙwayoyin ƙwayoyin cuta, Nivolumab da Ramucirumab duka Zaɓi magunguna ne.
Bugu da ƙari, yawancin masu ciwon hanta suna da ciwon hanta, kuma majiyyaci iri ɗaya, sassan jiki guda a lokaci guda, akwai cututtuka guda biyu mabanbanta. Nau'i daya shine cututtukan hanta na asali, ciki har da hepatitis, ko ciwon hanta na viral, ko ciwon hanta na giya, hanta mai kitse, cirrhosis, ana iya samun rashin aikin hanta da sauran matsaloli. Kashi na biyu shi ne cutar kansar hanta da ta ci gaba sosai. Wadannan cututtuka guda biyu suna shafar juna kuma suna haifar da mummunar da'ira. Sabili da haka, ya zama dole a ba da la'akari sosai ga tsarin ganewar asali da magani, don hana asarar juna. A cikin 'yan shekarun nan, an ba da shawarar cewa a gudanar da maganin rigakafi da rigakafin hanta a lokaci guda. Wannan kuma wani ci gaba ne da aka samu wajen maganin ciwon hanta.
